GlassScriptPhysician profile
Gerardo Bueso
NPI 1578658001
$21,304.34
in general payments reported to CMS, 2019-2025
70 companies · $3,214 in 2025
The $3,214 reported for 2025 was more than what 84% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,648 · 2020: $2,519 · 2021: $3,253 · 2022: $3,969 · 2023: $3,021 · 2024: $2,681 · 2025: $3,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,618 · Travel and Lodging: $225 · Education: $73.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,617.74 |
| Travel and Lodging | $224.86 |
| Education | $73.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,249.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $1,914.81 | 2020-2025 | Gallant, Freestyle Libre, Diamondback Peripheral |
| Mannkind Corporation | $1,471.19 | 2019-2025 | Afrezza |
| Amgen INC. | $1,165.22 | 2019-2025 | Tepezza, Evenity, Prolia |
| Lilly USA, LLC | $982.93 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $967.54 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $899.20 | 2021-2025 | |
| Amarin Pharma, INC. | $858.56 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $818.88 | 2020-2024 | Lokelma, Farxiga |
| Corcept Therapeutics | $775.42 | 2019-2025 | Korlym |
| Zealand Pharma US, INC. | $760.04 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $641.15 | 2019-2025 | |
| Dexcom, INC. | $587.34 | 2019-2025 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $536.50 | 2021-2025 | Isturisa, Signifor Lar |
| Abbvie INC. | $513.92 | 2019-2025 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $478.11 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Horizon Therapeutics Plc | $417.67 | 2019-2023 | Tepezza |
| Xeris Pharmaceuticals, INC. | $411.50 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Novartis Pharmaceuticals Corporation | $367.48 | 2022-2025 | |
| Esperion Therapeutics, INC. | $356.16 | 2020-2025 | Nexletol |
| Ascendis Pharma Endocrinology INC | $343.69 | 2023-2025 | Yorvipath |
| Merck Sharp & Dohme LLC | $248.08 | 2019-2025 | Capvaxive, Gardasil 9 |
| Regeneron Healthcare Solutions, INC. | $231.65 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $221.97 | 2020-2023 | Gattex |
| Cequr Corporation | $212.57 | 2022-2025 | Cequr Simplicity |
| Janssen Pharmaceuticals, INC | $195.47 | 2019-2020 | |
| Allergan, INC. | $172.95 | 2019-2020 | |
| Valeritas, INC. | $167.53 | 2019 | |
| Amneal Pharmaceuticals LLC | $156.24 | 2021-2023 | Unithroid |
| Beta Bionics, INC. | $149.98 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Vivus LLC | $146.44 | 2019-2023 | Qsymia |
| Medtronic Minimed, INC. | $143.79 | 2019-2020 | |
| Exact Sciences Corporation | $123.04 | 2023-2024 | Cologuard Collection Kit |
| Becton, Dickinson and Company | $115.63 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $110.19 | 2021-2022 | |
| Antares Pharma, INC. | $109.68 | 2019-2022 | |
| Astellas Pharma US INC | $106.05 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $102.55 | 2025 | |
| Radius Health, INC. | $95.77 | 2019-2025 | Tymlos |
| Ibsa Pharma INC. | $94.34 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.41 | 2022 | |
| Intuity Medical INC | $82.00 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Kyowa Kirin, INC. | $65.25 | 2024-2025 | Crysvita |
| Eusa Pharma (US) LLC | $59.90 | 2022 | |
| Amryt Pharma Holdings LTD | $56.95 | 2022-2023 | Mycapssa |
| Shire North American Group INC | $56.64 | 2019 | |
| Averitas Pharma INC. | $52.25 | 2025 | Qutenza |
| Opko Pharmaceuticals, LLC | $47.82 | 2019 | |
| Pfizer INC. | $47.08 | 2019-2020 | |
| Alvogen INC | $45.62 | 2025 | Teriparatide |
| Insulet Corporation | $40.64 | 2019 | |
| Tandem Diabetes Care, INC. | $33.22 | 2019 | |
| Lifescan, INC. | $31.64 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $31.47 | 2019-2020 | |
| Eisai INC. | $25.62 | 2019 | |
| Sequel Med Tech, LLC | $24.51 | 2025 | Twiist |
| Gilead Sciences, INC. | $18.57 | 2019 | |
| Kvk-Tech, INC. | $16.40 | 2019 | |
| Tolmar, INC. | $14.91 | 2024 | |
| Endo Pharmaceuticals INC. | $13.93 | 2020 | |
| Avvisto Therapeutics, LLC | $13.47 | 2025 | Cycloset |
| Currax Pharmaceuticals LLC | $11.05 | 2021 | |
| Emd Serono, INC. | $10.97 | 2019 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,207.54 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerardo Bueso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.